Lai Bun-Yueh, Chen Tzung-Yan, Huang Shou-Hsien, Kuo Tien-Fen, Chang Ting-Hsiang, Chiang Chih-Kang, Yang Meng-Ting, Chang Cicero Lee-Tian
Chun-Yueh Biomedical Technology Co., Ltd., Taipei 116, Taiwan.
Agricultural Biotechnology Research Center, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan ; Institute of Biotechnology, National Taiwan University, Taipei 106, Taiwan.
Evid Based Complement Alternat Med. 2015;2015:832314. doi: 10.1155/2015/832314. Epub 2015 Mar 18.
B. pilosa has long been purported to have antidiabetes activity, but despite the advancement in phytochemistry and animal models of diabetes, no human clinical trials have been conducted to date. Here, we evaluated the effect of a B. pilosa formulation on fasting blood glucose (FBG), fasting serum insulin, and glycosylated hemoglobin A1c (HbA1c) in diabetic subjects. The B. pilosa formulation reduced the level of FBG and HbA1c in diabetics but increased fasting serum insulin in healthy subjects. Moreover, combination of B. pilosa formulation with antidiabetic drugs had better glycemic control in diabetics. The homeostatic model assessment (HOMA) data suggested that the antidiabetic activity of this formulation was via improvement of β-cell function. We also tested the safety of the B. pilosa formulation in healthy subjects and observed no obvious side effects. We conclude that B. pilosa has potential as an antidiabetes treatment.
长期以来，人们一直声称白凤菜具有抗糖尿病活性，但尽管植物化学和糖尿病动物模型取得了进展，迄今为止尚未进行人体临床试验。在此，我们评估了白凤菜制剂对糖尿病患者空腹血糖（FBG）、空腹血清胰岛素和糖化血红蛋白A1c（HbA1c）的影响。白凤菜制剂降低了糖尿病患者的FBG和HbA1c水平，但增加了健康受试者的空腹血清胰岛素水平。此外，白凤菜制剂与抗糖尿病药物联合使用对糖尿病患者的血糖控制效果更好。稳态模型评估（HOMA）数据表明，该制剂的抗糖尿病活性是通过改善β细胞功能实现的。我们还测试了白凤菜制剂在健康受试者中的安全性，未观察到明显的副作用。我们得出结论，白凤菜具有作为抗糖尿病治疗药物的潜力。
Zotero 插件